A pilot study using nabilone for symptomatic treatment in Huntington's disease
Identifieur interne : 002473 ( Main/Curation ); précédent : 002472; suivant : 002474A pilot study using nabilone for symptomatic treatment in Huntington's disease
Auteurs : Adrienne Curtis [Royaume-Uni] ; Ian Mitchell [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Hugh Rickards [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-11-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Anti-Anxiety Agents (therapeutic use), Behavioral Symptoms (drug therapy), Behavioral Symptoms (etiology), Cannabinoid, Chorea, Cognition Disorders (drug therapy), Cognition Disorders (etiology), Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Dronabinol (analogs & derivatives), Dronabinol (therapeutic use), Female, Humans, Huntington Disease (complications), Huntington Disease (drug therapy), Huntington disease, Huntington's disease, Male, Mental disorder, Middle Aged, Nabilone, Nervous system diseases, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects, Treatment, cannabinoids, chorea, nabilone, psychiatric symptoms.
- MESH :
- chemical , analogs & derivatives : Dronabinol.
- chemical , therapeutic use : Anti-Anxiety Agents, Dronabinol.
- complications : Huntington Disease.
- drug therapy : Behavioral Symptoms, Cognition Disorders, Huntington Disease.
- etiology : Behavioral Symptoms, Cognition Disorders.
- Adult, Aged, Cross-Over Studies, Disability Evaluation, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Outcome Assessment (Health Care), Pilot Projects.
Abstract
Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22809
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E41
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E41
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001075
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B27
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001B27
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001F76
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002856
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002856
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002856
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002D34
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D09
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002010
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000F99
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003096
Links to Exploration step
ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22809</idno>
<idno type="url">https://api.istex.fr/document/61E6C434C0A8437E3F399E156F16677D97B934DF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002E41</idno>
<idno type="wicri:Area/Istex/Curation">002E41</idno>
<idno type="wicri:Area/Istex/Checkpoint">001075</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19845035</idno>
<idno type="wicri:Area/PubMed/Corpus">001B27</idno>
<idno type="wicri:Area/PubMed/Curation">001B27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F76</idno>
<idno type="wicri:Area/Ncbi/Merge">002856</idno>
<idno type="wicri:Area/Ncbi/Curation">002856</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002856</idno>
<idno type="wicri:Area/Main/Merge">002D34</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0036269</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D09</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002010</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F99</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:Area/Main/Merge">003096</idno>
<idno type="wicri:Area/Main/Curation">002473</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham School of Psychology, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-11-15">2009-11-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">15</biblScope>
<biblScope unit="page" from="2254">2254</biblScope>
<biblScope unit="page" to="2259">2259</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<idno type="DOI">10.1002/mds.22809</idno>
<idno type="ArticleID">MDS22809</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Behavioral Symptoms (drug therapy)</term>
<term>Behavioral Symptoms (etiology)</term>
<term>Cannabinoid</term>
<term>Chorea</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dronabinol (analogs & derivatives)</term>
<term>Dronabinol (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Huntington Disease (complications)</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington disease</term>
<term>Huntington's disease</term>
<term>Male</term>
<term>Mental disorder</term>
<term>Middle Aged</term>
<term>Nabilone</term>
<term>Nervous system diseases</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
<term>Treatment</term>
<term>cannabinoids</term>
<term>chorea</term>
<term>nabilone</term>
<term>psychiatric symptoms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cannabinoïde</term>
<term>Chorée de Huntington</term>
<term>Nabilone</term>
<term>Pathologie du système nerveux</term>
<term>Syndrome choréique</term>
<term>Traitement</term>
<term>Trouble psychiatrique</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2009:Curtis A:a:pilot:study"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University of Birmingham School of Psychology</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0036269</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 10-0036269 INIST</idno>
<idno type="RBID">Pascal:10-0036269</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D09</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002010</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000F99</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:Area/Main/Merge">003096</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>University of Birmingham School of Psychology</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust</s1>
<s2>Edgbaston, Birmingham</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cannabinoid</term>
<term>Chorea</term>
<term>Huntington disease</term>
<term>Mental disorder</term>
<term>Nabilone</term>
<term>Nervous system diseases</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chorée de Huntington</term>
<term>Syndrome choréique</term>
<term>Trouble psychiatrique</term>
<term>Pathologie du système nerveux</term>
<term>Nabilone</term>
<term>Traitement</term>
<term>Cannabinoïde</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double-blind, placebo-controlled, cross-over study of nabilone versus placebo. Primary outcome, Unified Hunting-ton's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: -1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: -3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: -0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/mds.22809</idno>
<idno type="url">https://api.istex.fr/document/61E6C434C0A8437E3F399E156F16677D97B934DF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002E41</idno>
<idno type="wicri:Area/Istex/Curation">002E41</idno>
<idno type="wicri:Area/Istex/Checkpoint">001075</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Curtis A:a:pilot:study</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19845035</idno>
<idno type="wicri:Area/PubMed/Corpus">001B27</idno>
<idno type="wicri:Area/PubMed/Curation">001B27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001F76</idno>
<idno type="wicri:Area/Ncbi/Merge">002856</idno>
<idno type="wicri:Area/Ncbi/Curation">002856</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002856</idno>
<idno type="wicri:Area/Main/Merge">002D34</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A pilot study using nabilone for symptomatic treatment in Huntington's disease</title>
<author><name sortKey="Curtis, Adrienne" sort="Curtis, Adrienne" uniqKey="Curtis A" first="Adrienne" last="Curtis">Adrienne Curtis</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mitchell, Ian" sort="Mitchell, Ian" uniqKey="Mitchell I" first="Ian" last="Mitchell">Ian Mitchell</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham School of Psychology, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Patel, Smitaa" sort="Patel, Smitaa" uniqKey="Patel S" first="Smitaa" last="Patel">Smitaa Patel</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham Clinical Trials Unit, Division of Medical Sciences, Robert Aitken Institute, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rickards, Hugh" sort="Rickards, Hugh" uniqKey="Rickards H" first="Hugh" last="Rickards">Hugh Rickards</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neuropsychiatry, Birmingham and Solihull Mental Health Foundation Trust, Edgbaston, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-11-15">2009-11-15</date>
<biblScope unit="vol">24</biblScope>
<biblScope unit="issue">15</biblScope>
<biblScope unit="page" from="2254">2254</biblScope>
<biblScope unit="page" to="2259">2259</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">61E6C434C0A8437E3F399E156F16677D97B934DF</idno>
<idno type="DOI">10.1002/mds.22809</idno>
<idno type="ArticleID">MDS22809</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Anti-Anxiety Agents (therapeutic use)</term>
<term>Behavioral Symptoms (drug therapy)</term>
<term>Behavioral Symptoms (etiology)</term>
<term>Cognition Disorders (drug therapy)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Dronabinol (analogs & derivatives)</term>
<term>Dronabinol (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Huntington Disease (complications)</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington's disease</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
<term>cannabinoids</term>
<term>chorea</term>
<term>nabilone</term>
<term>psychiatric symptoms</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Anxiety Agents</term>
<term>Dronabinol</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Behavioral Symptoms</term>
<term>Cognition Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Cross-Over Studies</term>
<term>Disability Evaluation</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Outcome Assessment (Health Care)</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and behavior, and neuropsychiatric inventory (NPI). 44 randomized patients received either nabilone (1 or 2 mg) followed by placebo (n = 22), or placebo followed by nabilone (n = 22). Recruiting was straightforward. Nabilone safe and well tolerated, no psychotic episodes. Assessment of either dose of nabilone versus placebo showed a treatment difference of 0.86 (95% CI: −1.8 to 3.52) for total motor score; 1.68 (95% CI: 0.44 to 2.92) for chorea; 3.57 (95% CI: −3.41 to 10.55) for UHDRS cognition; 4.01 (95% CI: −0.11 to 8.13) for UHDRS behavior, and 6.43 (95% CI: 0.2 to 12.66) for the NPI. Larger longer RCT of nabilone in HD is feasible and warranted. © 2009 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002473 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002473 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:61E6C434C0A8437E3F399E156F16677D97B934DF |texte= A pilot study using nabilone for symptomatic treatment in Huntington's disease }}
This area was generated with Dilib version V0.6.23. |